Each row is a biotech company with active signals from FDA filings, SEC disclosures, clinical trial databases, and insider trading records. Use the filters below to surface the companies worth researching before the market moves.
A–F letter grade based on the quality and timing of upcoming catalysts — PDUFA dates, AdCom votes, Phase 3 readouts. A = multiple near-term high-impact events. F = nothing on the calendar.
0–100 composite measuring signal density across all data sources. A score of 80+ means multiple independent signals are firing simultaneously — insider buys, clinical activity, and an approaching FDA date, for example.
A scheduled event with a known date that can move a biotech stock significantly — FDA approval decisions (PDUFA), advisory committee votes (AdCom), Phase 2/3 trial data readouts, and earnings.
Tags showing which data sources fired. PDUFA = approval date. Insider Buy = executive bought shares. Dilution = SEC filing suggests offering risk.
DilutionWatch score (0–100) measuring SEC-filing evidence of upcoming share dilution. CRITICAL = active S-3/ATM shelf, offering likely this quarter. LOW = healthy balance sheet, no shelf detected.
Estimated months of cash remaining at the current burn rate from DilutionWatch. A company cannot survive to its PDUFA date without cash. Under 6 months = likely to raise capital soon.
| Ticker↕ | Company↕ | Sector↕ | Score▼ | Grade↕ | Dilution Risk↕ | Cash↕ | Signals | Next Catalyst↕ | |
|---|---|---|---|---|---|---|---|---|---|
| EYPT | EyePoint, Inc. | Ophthalmology | 83.45 | A | — | — | — | — | |
| MLTX | MoonLake Immunotherapeutics | Immunology | 80.53 | A | — | — | — | — | |
| GRFS | Grifols SA | Plasma Therapeutics | 74.85 | B | — | — | — | — | |
| ARGX | argenx SE | Autoimmune | 73.97 | B | — | — | — | — | |
| NUVB | Nuvation Bio | Oncology | 73.62 | B | — | — | — | — | |
| BBIO | BridgeBio Pharma | Oncology | 73.16 | B | — | — | — | — | |
| COGT | Cogent Biosciences | Precision Medicine | 71.56 | B | — | — | — | — | |
| TENX | Tenax Therapeutics, Inc. | Biotech / Pharma | 70.79 | B | — | — | — | — | |
| CAPR | Capricor Therapeutics, Inc. | Biotech / Pharma | 70.34 | B | — | — | — | — | |
| RNAC | Cartesian Therapeutics, Inc. | Biotech / Pharma | 69.68 | B | — | — | — | — | |
| VRDN | Viridian Therapeutics, Inc. | Biotech / Pharma | 63.85 | C | — | — | — | — | |
| IBRX | ImmunityBio, Inc. | Biotech / Pharma | 63.26 | C | — | — | — | — | |
| CORT | Corcept Therapeutics | Endocrinology | 62.53 | C | — | — | — | — | |
| KURA | Kura Oncology, Inc. | Oncology | 62.52 | C | — | — | — | — | |
| RCUS | Arcus Biosciences | Immuno-Oncology | 62.1 | C | — | — | — | — | |
| TVTX | Travere Therapeutics | Nephrology | 62.1 | C | — | — | — | — | |
| LBRX | LB Pharmaceuticals Inc | Biotech / Pharma | 62.01 | C | — | — | — | — | |
| KPTI | Karyopharm Therapeutics | Oncology | 61.21 | C | — | — | — | — | |
| CYTK | Cytokinetics Inc | Cardiovascular | 60.19 | C | — | — | — | — | |
| BNTX | BioNTech SE | mRNA Therapeutics | 60.14 | C | — | — | — | — | |
| MGNX | MacroGenics Inc | Oncology | 59.03 | C | — | — | — | — | |
| MRNA | Moderna Inc | mRNA Therapeutics | 59.03 | C | — | — | — | — | |
| AGIO | Agios Pharmaceuticals | Rare Disease | 58.92 | C | — | — | — | — | |
| KOD | Kodiak Sciences Inc | Biotech / Pharma | 58.74 | C | — | — | — | — | |
| VIR | Vir Biotechnology, Inc. | Biotech / Pharma | 57.92 | C | — | — | — | — | |
| IMVT | Immunovant Inc | Autoimmune | 57.74 | C | — | — | — | — | |
| HRMY | Harmony Biosciences | Neuroscience | 57.34 | C | — | — | — | — | |
| WVE | Wave Life Sciences Ltd. | Biotech / Pharma | 57.16 | C | — | — | — | — | |
| MDGL | Madrigal Pharmaceuticals | Liver Disease | 56.78 | C | — | — | — | — | |
| ONCY | Oncolytics Biotech, Inc. | Oncology | 56.5 | C | — | — | — | — | |
| PBYI | Puma Biotechnology Inc | Biotech / Pharma | 56.47 | C | — | — | — | — | |
| CLYM | Climb Bio, Inc. | Biotech / Pharma | 56.45 | C | — | — | — | — | |
| VERA | Vera Therapeutics | Nephrology | 56.19 | C | — | — | — | — | |
| MIRM | Mirum Pharmaceuticals | Liver Disease | 56 | C | — | — | — | — | |
| OCUL | Ocular Therapeutix | Ophthalmology | 55.75 | C | — | — | — | — | |
| INBX | Inhibrx Inc | Oncology / Rare | 55.67 | C | — | — | — | — | |
| ADCT | ADC Therapeutics SA | Biotech / Pharma | 55.63 | C | — | — | — | — | |
| AXSM | Axsome Therapeutics | Neuroscience | 55.62 | C | — | — | — | — | |
| CRDF | Cardiff Oncology, Inc. | Oncology | 55.24 | C | — | — | — | — | |
| IONS | Ionis Pharmaceuticals | Antisense Therapeutics | 55.22 | C | — | — | — | — | |
| MPLT | MapLight Therapeutics, Inc. | Biotech / Pharma | 55.03 | C | — | — | — | — | |
| SUPN | Supernus Pharmaceuticals, Inc. | Biotech / Pharma | 54.83 | C | — | — | — | — | |
| SYRE | Spyre Therapeutics, Inc. | Biotech / Pharma | 54.72 | C | — | — | — | — | |
| OLMA | Olema Pharmaceuticals, Inc. | Biotech / Pharma | 54.4 | C | — | — | — | — | |
| CELC | Celcuity Inc | Oncology | 53.98 | C | — | — | — | — | |
| CADL | Candel Therapeutics, Inc. | Biotech / Pharma | 53.74 | C | — | — | — | — | |
| TRVI | Trevi Therapeutics, Inc. | Biotech / Pharma | 53.58 | C | — | — | — | — | |
| MLYS | Mineralys Therapeutics, Inc. | Biotech / Pharma | 53.57 | C | — | — | — | — | |
| NBIX | Neurocrine Biosciences | Neuroscience | 52.82 | C | — | — | — | — | |
| RVMD | Revolution Medicines | Precision Oncology | 52.82 | C | — | — | — | — |
Not financial advice. Data by Guerilla Finance Inc. for informational purposes only. Always conduct your own due diligence.